

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

TARO PHARMACEUTICAL INDUSTRIES LTD

Form 6-K

April 10, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2008

Commission File Number 000-22286

Taro Pharmaceutical Industries Ltd.
(Translation of registrant's name into English)

14 Hakitor Street, Haifa Bay 26110, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_____.

The Company is filing the attached Statement of Cash Flows to supplement its
form 6-K report filed on February 20, 2008. This information was not included in
the form 6-K filed on February 20th, because it was not available at that time.
The Company cautions that the Statement of Cash Flows is both unaudited and
subject to further review and possible change. Additionally, this Statement of
Cash Flows does not provide complete financial information and is subject to
audit by the Company's outside auditors. This Statement of Cash Flows has not
been and will not be subject to quarterly review procedures.

- Statement of Cash Flows to follow -

TARO PHARMACEUTICAL INDUSTRIES LTD.

SUMMARY CONSOLIDATED STATEMENT OF CASHFLOWS

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

(US dollars in thousands)

Operating Activities:

Net income

Adjustments required to reconcile net income to net cash provided by operating activities:

- Depreciation and amortization
- Stock based compensation
- Gain on sales of property, plant and equipment
- Increase in fair value of derivative instruments
- Increase in long-term debt due to currency fluctuations
- Amortization of deferred revenue
- Increase in trade receivables
- Increase in other receivables and prepaid tax
- Increase in inventories
- Foreign exchange effect on intercompany balances
- Decrease in trade and other payables and accruals

Net cash provided by operating activities

Investing Activities:

Purchase of property plant & equipment, net of related grants

Investment in other intangible assets

Proceeds from sale of marketable securities

Proceeds from sales of property, plant and equipment

Net cash provided by investing activities

Financing Activities:

Proceeds from issuance of shares, net

Repayments of long term debt

Repayments of short-term bank debt, net

Net cash provided by financing activities

Effect of exchange rate changes

Edgar Filing: TARO PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

Net increase in cash

Cash at beginning of period

Cash at end of period

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 10, 2008

TARO PHARMACEUTICAL INDUSTRIES LTD.

By: /s/ Tal Levitt

Name: Tal Levitt

Title: Director and Secretary